Fibrillex on fast track to ’05 filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurochem hopes to complete Phase II/III clinical trial for its fast-track drug candidate Fibrillex by January 2005, with a subsequent 2005 NDA submission. The two-year, randomized, double-blind, placebo-controlled, parallel-design study in secondary amyloid A amyloidosis is ongoing. Fibrillex is a glycosaminoglycan mimetic that treats AA amyloidosis by preventing amyloid fibril formation...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.